Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma

The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma. 

Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma

Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.

Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL

Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2 trial.

Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Panelists discuss how the treatment approach for a 67-year-old man with stage IIIB+ non–small cell lung cancer (NSCLC) awaiting mutation testing involves balancing the urgency of initiating therapy with the importance of molecular testing to guide targeted treatment decisions.

My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC 

Video Series

Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

Videos

Panelists discuss how genetic testing and RET-targeted therapies play a crucial role in guiding the treatment of advanced NSCLC, with a focus on optimizing first-line therapy and managing challenges in molecular testing and treatment sequencing.

Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

EP: 1.Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

Latest Conference Coverage